Hessian Regularized $$L_{2,1}$$-Nonnegative Matrix Factorization and Deep Learning for miRNA–Disease Associations Prediction

Han, Guo-Sheng; Gao, Qi; Peng, Ling-Zhi; Tang, Jing

doi:10.1007/s12539-023-00594-8

Interdiscip Sci Comput Life Sci

2023

DOI: 10.1007/s12539-023-00594-8

|View full text |Cite

Hessian Regularized $$L_{2,1}$$-Nonnegative Matrix Factorization and Deep Learning for miRNA–Disease Associations Prediction

Guo-Sheng Han,

Qi Gao,

Ling-Zhi Peng

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

MicroRNAs and angiosarcoma: are there promising reports?

Modarresi Chahardehi,

Afrooghe,

Emtiazi

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

In recent years, microRNAs (miRNAs) have garnered increasing attention for their potential implications in cancer pathogenesis, functioning either as oncogenes or tumor suppressors. Notably, angiosarcoma, along with various other cardiovascular tumors such as lipomas, rhabdomyomas, hemangiomas, and myxomas, has shown variations in the expression of specific miRNA subtypes. A substantial body of evidence underscores the pivotal involvement of miRNAs in the genesis of angiosarcoma and certain cardiovascular tumors. This review aims to delve into the current literature on miRNAs and their prospective applications in cardiovascular malignancies, with a specific focus on angiosarcoma. It comprehensively covers diagnostic methods, prognostic evaluations, and potential treatments while providing a recapitulation of angiosarcoma’s risk factors and molecular pathogenesis, with an emphasis on the role of miRNAs. These insights can serve as the groundwork for designing randomized control trials, ultimately facilitating the translation of these findings into clinical applications. Moving forward, it is imperative for studies to thoroughly scrutinize the advantages and disadvantages of miRNAs compared to current diagnostic and prognostic approaches in angiosarcoma and other cardiovascular tumors. Closing these knowledge gaps will be crucial for harnessing the full potential of miRNAs in the realm of angiosarcoma and cardiovascular tumor research.

show abstract

MicroRNAs and angiosarcoma: are there promising reports?

Modarresi Chahardehi,

Afrooghe,

Emtiazi

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Hessian Regularized $$L_{2,1}$$-Nonnegative Matrix Factorization and Deep Learning for miRNA–Disease Associations Prediction

Cited by 1 publication

References 53 publications

MicroRNAs and angiosarcoma: are there promising reports?

MicroRNAs and angiosarcoma: are there promising reports?

Contact Info

Product

Resources

About